Creative Planning retains $4.29 Million stock holdings in
Bio-Techne Corp while
PNC Financial Services Group Inc. and
Aviva PLC have reduced their stakes. Bio-Techne secures an exclusive license for AI-Designed NovoBody™ Duo molecules from
Monod Bio, an achievement set to expand the recombinant protein portfolio significantly. Market analysts
Argus Research, remain positive with their buy recommendation for the tech giant.
Rothschild Investment LLC and
Dorsey & Whitney Trust CO LLC have increased their shares in the company.
UBS also maintains a buy recommendation for the company. Bio-Techne, however, posted mixed results for the Q1 2026 earnings, meeting earnings expectations but missing on revenues. The company’s
ProximityScope Spatial Biology Assay has garnered interest from investors. Bio-Techne continues to collaborate with Oxford Nanopore Technologies to expand its genetic portfolio through 2032. The recent dividend declaration and potential for future growth make the company's stocking holding a considerable long-term investment. Finally, unrecognized factors led to a slump in the company's stock, but market experts believe this could create an opening for potential investors.
Bio-Techne Corp TECH News Analytics from Fri, 02 May 2025 07:00:00 GMT to Sat, 22 Nov 2025 09:01:28 GMT -
Rating 7
- Innovation 6
- Information 9
- Rumor -3
